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Edited by Peter BrzezinskiAbstract We have performed an in vitro study to investigate the
molecular basis of the aggregation kinetic of 1-40 b-amyloid pep-
tides (Ab and the possibility of aﬀecting this aggregation process
using an exogenous natural polycyclic pigment, hypericin (Hyp).
The eﬀect of Hyp on the self-assembly process at diﬀerent times
of the aggregation kinetic has been investigated utilizing a chap-
eron-like molecule, a-crystallin. Circular dichroism and ﬂuores-
cence results suggest that Hyp can associate to precursors of the
mature ﬁbrils and perturb the aggregation process through inter-
molecular interactions with the Ab peptides.
Structured summary:
MINT-6742984: 1-40 beta-amyloid peptide (uniprotkb:P05067)
and 1-40 beta-amyloid peptide (uniprotkb:P05067) bind
(MI:0407) by circular dichroism (MI:0016)
MINT-6743002: 1-40 beta-amyloid peptide (uniprotkb:P05067)
and 1-40 beta-amyloid peptide (uniprotkb:P05067) bind
(MI:0407) by light scattering (MI:0067)
MINT-6743012: 1-40 beta-amyloid peptide (uniprotkb:P05067)
and 1-40 beta-amyloid peptide (uniprotkb:P05067) bind
(MI:0407) by classical ﬂuorescence spectroscopy (MI:0017)
 2008 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Diﬀerent neurodegenerative disorders, like Huntingtons and
Alzheimers diseases, have in common the presence of insolu-
ble protein aggregates near the site of disease [1–3]. These
‘‘amyloid’’ aggregates share physicochemical features: a ﬁbril-
lar morphology, a predominantly b-sheet secondary structure,
birefringence upon staining with Congo red, insolubility in
common solvents and detergents and protease-resistance. In
the case of Alzheimers disease (AD) typical senile plaques
are observed, made of extracellular deposits of b-amyloid pep-
tide (Ab) ﬁbrils.Abbreviations: Ab, b-amyloid peptides; AD, Alzheimers disease;
Hyp, hypericin; ThT, thioﬂavine T
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doi:10.1016/j.febslet.2008.08.039Ab, composed of 39–43 aminoacids, derives from the pro-
cessing of the cell surface glycoprotein, amyloid precursor pro-
tein (APP), made up of 770 aminoacids, involved in nuclear
signalling. The polymerization of Ab, yielding well-ordered ﬁ-
brils, is characterized by multiple transitional species: initial
seeds, soluble small oligomers, protoﬁbrils and insoluble poly-
mers, amyloid ﬁbrils with a b-sheet conformation.
Fibril formation is a polymerization process, described by a
sigmoid curve, recently suggested to be a three-stage process
consisting of protein misfolding, nucleation, and ﬁbril elonga-
tion [4]. In this phenomenon a key role is played by forces
common to all proteins, without any meaningful dependence
on the speciﬁc peptide sequence: hydrophobic interactions,
backbone hydrogen bonding, stacking interactions.
For a long while the conventional view has been that AD
pathology is brought about by the amyloid ﬁbrils found in
the senile plaques, but more recently it has been suggested that
the main neurotoxic species would be the soluble oligomeric
species [5–7]. These oligomers seem to be prone to form pores,
potentially inducing cell dysfunction via inappropriate mem-
brane permeabilization [8].
Diﬀerent therapeutic strategies are currently under investiga-
tions: (1) inhibition of Ab production, (2) blockade of Ab in-
duced inﬂammation, (3) modulation of cholesterol
homeostasis and (4) inhibition of Ab polymerization.
We will focus our attention on this last approach, being
aware that it is diﬃcult to assess which is the best strategy be-
cause each of them has some limitations as well as some prom-
ising perspectives. It is noteworthy to underline that Ab is a
normal constituent of biological ﬂuids and, at low basal levels,
it has been shown to down regulate synaptic transmission [9],
so that inhibiting this physiological activity could be harmful
and give rise to toxic side eﬀects.
Conformational constrains can play a key role in ﬁbrillo-
genesis [10] and it is crucial to investigate and clarify if and
how this process can be aﬀected by appropriate drugs. Pep-
tide–peptide interactions resulting in self-assembly phenom-
ena of Ab yielding ﬁbrils can be modulated and inﬂuenced
by small organic molecules [11–13] that might also be eﬀective
therapeutic tools to ideally target both oligomeric and ﬁbrillar
species.
Here we report the results of an in vitro study of the eﬀects
of a-crystallin and of the natural pigment hypericin (Hyp) on
Ab ﬁbrillogenesis. a-Crystallin is a chaperone-like protein
[14] that has been reported to interact also with Ab [15,16].
Hyp is a natural pigment, extracted from Hypericum
perforatum, widely used as a mild antidepressant and recently
suggested to have a neuroprotective eﬀect [17,18]. Hyp is ablished by Elsevier B.V. All rights reserved.
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with numerous biomolecules by means of weak, non-covalent
interactions [19] – that might disrupt the molecular architec-
tures precursors of Ab ﬁbrils [20–23].0
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t0 t12. Materials and methods
Thioﬂavin T (ThT), a-crystallin and Hyp (all from Sigma) were used
without further puriﬁcation. Ab (1-40) were purchased from Biopep-
tide Co. and used after handling according to Fezoui et al. [24].
Aggregation of Ab was induced rising the temperature to 60 C in
the thermostated cell holder of a Perkin–Elmer 50 LS B spectroﬂuo-
rimeter, equipped with a magnetic stirrer. Both excitation and emission
monochromators were set at 405 nm to monitor the aggregation pro-
cess through light scattering. Unless otherwise stated, in all aggrega-
tion studies Ab concentration was 150 lM.
Aliquots of a-crystallin and Hyp were added to the peptide sample
immediately before putting the cuvette into the cell holder or during
the measurement at diﬀerent times of the aggregation curve: lag phase,
rising phase and saturation phase.
Fluorescence spectra were measured by means of the same
Perkin–Elmer 50 LS B spectroﬂuorimeter.
Optical absorption spectra were measured with a JASCO 7850
spectrophotometer.
Circular dichroism (CD) measurements were performed by means of
JASCO J-500A and J-710 (kindly made available by Profs. Di Bari and
Pescitelli, Chemistry Department, University of Pisa) spectropolarim-
eters. Spectra recorded with the J-710 instrument have also been ana-
lyzed by means of the CONTINN-LL procedure, using the CDPro
package [25]. All CD spectra were recorded in 0.05 cm path-length cuv-
ettes. To measure CD spectra in the diﬀerent phases of the kinetics,
200 ll were taken from the sample stirred at 60 C and transferred into
the CD cuvette at room temperature.-7
Wavelength (nm)
Fig. 1. (A) Time-course of the aggregation process at 60 C of three
typical 150 lM Ab samples; (B) CD spectra of 150 lM Ab in diﬀerent
phases of the aggregation process (t0, beginning of the lag phase; t1,
beginning of the polymerization process; t2, beginning of the satura-
tion phase; t3, saturation phase).3. Experimental results and discussion
As shown in Fig. 1A the aggregation process starts and
reaches a saturation level in several hours. Besides minor dif-
ferences in the duration of the lag phase, the proﬁle of the
aggregation process is quite reproducible. As shown in
Fig. 1B, CD results indicate that the spectrum of the mono-
mer/oligomer has a prevalent random-coil structure (3% a-he-
lix, 41% b-sheet, 56% random coil), with a minimum at about
200–205 nm (curves t0 and t1), and that the aggregation pro-
cess is parallel to the appearance of a band mainly due to a
b-sheet structure (11% a-helix, 56% b-sheet, 41% random coil;
band centered at about 215 nm, curves t2 and t3), the intensity
of which increases with time.
3.1. Hyp as a ﬂuorescent probe
Thioﬂavin T (ThT) is a widely used ﬂuorescent indicator of
the presence of Ab ﬁbrils: its ﬂuorescence quantum yield in-
creases when bound to amyloid ﬁbrils, whilst when unbound
is intrinsically quenched.
Hyp has ﬂuorescent properties that make this pigment a
quite reliable probe: in aqueous solutions, in fact, Hyp mole-
cules give rise to polydispersed non-ﬂuorescent aggregates,
but they easily associate to a large variety of proteins and
macromolecules thus yielding highly ﬂuorescent monomers
[26,27].
To estimate Hyp possible capability in revealing amyloid ﬁ-
brils, a comparative spectroscopic study has been carried out
in which Hyp and ThT ﬂuorescence have been measured in
the presence of increasing amounts of Ab ﬁbrils.As shown in Fig. 2, ThT is much more eﬃcient than Hyp in
revealing the presence of ﬁbrils. It is noteworthy to underline
that in the case of ThT, the ﬂuorescence increase is due to
the blockage of the rotation of the benzothiozole and benzami-
nic rings with respect to one another: a kind of ‘‘mechanical
eﬀect’’, similar to that obtained rising the solvent viscosity.
The fact that Hyp has been found to become ﬂuorescent
changing over from a non-ﬂuorescent polydispersed aggregate
form to a ﬂuorescent monomeric one, suggests that it can
interact also with substrates like b ﬁbrils.
In order to ﬁnd out if Hyp is able to reveal also pre-ﬁbrillar
forms, the b peptide aggregation has been blocked at diﬀerent
stages of the process and, in particular, at a pre-ﬁbrillar phase
by means of a molecular chaperone, a-crystallin [15,16].
The eﬀect of a-crystallin on the aggregation process mark-
edly depends on the phase in which it is added. Addition of
a-crystallin to the peptide solution before the aggregation ini-
tiates fully hinders the aggregation itself regardless of the used
concentrations from 0.5 down to 0.01 mg/ml (Fig. 3A).
Once the aggregation is ongoing, it is still possible to stop it
adding 0.1 mg/ml a-crystallin, whereas 0.01 mg/ml is appar-
ently completely ineﬀective and the aggregation curve perfectly
overlaps that of pure Ab (Fig. 3B).
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Fig. 2. Fluorescence intensity of (A) ThT (5 lM, kexc = 443 nm) and (B) Hyp (5 lM, kexc = 550 nm) in the presence of increasing amounts of Ab
mature ﬁbrils; (C) dose–eﬀect curves of ThT and Hyp ﬂuorescence in the presence of increasing amounts of Ab mature ﬁbrils.
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of the early misfolding of the aggregation-prone Ab even at
the lowest used concentrations.
Fluorescence spectra of ThT and Hyp have been measured
in the presence of Ab ﬁbrils, monomer and with 0.1 mg/ml
a-crystallin added before (inhibition) and after (partial inhibi-
tion) the aggregation process starts (Fig. 4A). ThT ﬂuores-
cence intensity is quite high when ﬁbrils are present and still
measurable in ‘‘partial inhibition’’ conditions. In the presence
of the monomer and in ‘‘inhibition’’ conditions no ThT ﬂuo-
rescence signal is detectable. In the case of Hyp, on the con-
trary, whereas no signiﬁcant ﬂuorescence is detected in the
presence of the monomer, a clear ﬂuorescence signal is ob-
served both in ‘‘partial inhibition’’ and ‘‘inhibition’’ conditions
(Fig. 4B). Control measurements have shown that neither ThT
nor Hyp ﬂuoresce in the presence of a-crystallin at the used
protein concentrations.
These results, therefore, indicate that Hyp can interact also
with the early precursors of the b-sheet ﬁbrils and/or protoﬁ-
brils, whereas ThT, in our experimental conditions, is not so
eﬀective in revealing primary ﬁbril precursors [7].
3.2. Hyp as an aggregation inhibitor
The fact that Hyp interacts also with the precursors of b-
sheet ﬁbrils has prompted the study of possible eﬀects of
Hyp on the aggregation kinetics of Ab.
In the presence of 105 M Hyp the aggregation process of
Ab seems to be either prevented or arrested, depending on
the aggregation phase in which the pigment is added. Fig. 5 re-ports the eﬀect of Hyp added at diﬀerent times of the aggrega-
tion process. The capability of Hyp of interacting with early-
self-assemblies of Ab and of disrupting the molecular architec-
tures that pave the way to ﬁbril formation is clearly suggested
by the results reported in Fig. 5, showing that no scattering
particle is formed if Hyp is added before the aggregation pro-
cess initiates. Similarly to what observed with a-crystallin, but
through a completely diﬀerent molecular mechanism, Hyp at a
concentration 105 M prevents or arrests the aggregation pro-
cess of Ab.
In order to obtain further information about the interaction
between Hyp and Ab, the previous experiment, with Hyp added
before the aggregation process begins, has been repeated mon-
itoring the Ab kinetics by means of time-course of Hyp ﬂuores-
cence as well as measuring CD spectra at three ‘‘strategic’’
times: t(i), t(r) and t(f) (see below).
As reported in Fig. 6A, Hyp ﬂuorescence starts rising from
the beginning, increases exponentially and reaches a saturation
level. This means that Hyp immediately interacts with Ab and
it is reasonable to suggest that the increase of Hyp ﬂuorescence
corresponds to the rise of Ab oligomer concentration which
the chromophore interacts with. The lack of any signiﬁcant
scattering (see Fig. 5) and the absence of ThT ﬂuorescence sig-
nal at t(f) (data not shown) exclude the formation of mature
ﬁbrils in these experimental conditions.
The results reported in Fig. 5 and in Fig. 6A can be ex-
plained assuming the occurrence of weak, non-covalent inter-
actions between Hyp and b peptides. These interactions
could consist in a number of components, including electro-
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A. Sgarbossa et al. / FEBS Letters 582 (2008) 3288–3292 3291static, van der Waals and solvophobic forces. Hyp could inter-
act with the p-electron system of b aromatic residues targeting
the amyloidogenic core and interfering with ﬁbril assembly, as
suggested in the case of polyphenols [21] and/or perturb the
hydrophobic forces that maintain in close contact the side
chains of the polypeptide thus having a disrupting eﬀect [22].0
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ﬁbrillar (ﬁbrils) forms of Ab and in the presence of Ab samples in which th
inhibition) blocked by a-crystallin.In the presence of Hyp, CD spectra of Ab (Fig. 6B) seem to
have substantially the same time-dependent behavior as that of
pure peptide: a transition from the initial random coil, with a
minimum at about 200–205 nm (curve t(i)), to the ﬁnal b-sheet
secondary structure (shoulder at about 215 nm, curve t(f)), this
predominant b-sheet structure being however due, in this case,
to the presence of oligomers and not of ﬁbrils.4. Concluding remarks
We have shown that, thanks to its structural characteristics
and peculiar spectroscopic features, Hyp can be easily used to
in vitro monitor the appearance of early aggregation states of
Ab peptides during the polymerization process. This may con-
tribute to stimulate further works on the structural character-
ization of these ﬁbrils precursors.0
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3292 A. Sgarbossa et al. / FEBS Letters 582 (2008) 3288–3292Moreover, our ﬁndings that Hyp can signiﬁcantly aﬀect and
interfere with the early stages of polymerization process, sug-
gest this natural aromatic molecule as an eﬀective aggregation
inhibitor, possibly exploitable for future therapeutic ap-
proaches to AD.Acknowledgments: Authors are deeply indebted to Profs. Lorenzo Di
Bari and Gennaro Pescitelli, Chemistry Department, Pisa University,
for their precious help in performing CD measurements and discussing
CD results.References
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